

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Mammalian target of rapamycin (mTOR; FRAP; RAFT1); mTOR complex 1 (mTORC1); mTORC2	<p>Studies in cell culture identified pyrazolopyrimidine analogs as mTOR inhibitors that could help treat cancer. In human renal and gliomal cancer cell lines, the lead compound inhibited mTORC1, mTORC2 and a rapamycin-resistant mutant variant of mTORC1. Results of ongoing work will be reported in upcoming publications.</p> <p>Novartis AG's oral mTOR inhibitor Certican/Afinitor everolimus is marketed to prevent organ transplant rejection, approved to treat renal cancer and in multiple Phase I through Phase III trials to treat a range of cancers.</p> <p>Exelixis Inc. and sanofi-aventis Group's XL765, a small molecule inhibitor of mTOR and phosphoinositide 3-kinase (PI3K), is in Phase I/II testing to treat brain cancer and non-small cell lung cancer (NSCLC) and Phase I testing to treat solid tumors.</p> <p>OSI Pharmaceuticals Inc.'s mTOR inhibitor OSI-027 is in Phase I testing to treat lymphoma.</p> <p><b>SciBX 2(42); doi:10.1038/scibx.2009.1563</b> Published online Oct. 29, 2009</p>	Patented by Pfizer Inc.; licensing status undisclosed	<p>Nowak, P. <i>et al. J. Med. Chem.</i>; published online Oct. 19, 2009; doi:10.1021/jm9012642</p> <p><b>Contact:</b> Pawel Nowak, Pfizer Pharma Therapeutics, Pearl River, N.Y. e-mail: <a href="mailto:nowakp@wyeth.com">nowakp@wyeth.com</a></p>